10-K: Seres Therapeutics Shifts Focus to I&I Amidst Going Concern Doubts

Seres Therapeutics, Inc. reports a strategic pivot towards inflammatory and immune diseases, pausing further investment in its lead infectious disease candidate SER-155's Phase 2 study due to funding needs, while detailing 2025 financial results including a net income from continuing operations.

Summary

• Seres Therapeutics is a clinical-stage company focused on novel live biotherapeutic products (LBPs) for medically vulnerable populations.
• The company successfully developed and obtained FDA approval for VOWST, the first orally administered microbiome biotherapeutic, which was sold to Nestlé Health Science in September 2024.
• The current pipeline includes SER-155, SER-603, and SER-147, with a strategic prioritization of inflammatory and immune (I&I) indications.
• SER-155 received Fast Track Designation in December 2023 and Breakthrough Therapy designation in December 2024 for reducing bacterial bloodstream infections (BSIs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients.
• Phase 1b study of SER-155 in allo-HSCT demonstrated a 77% relative risk reduction in bacterial BSIs and a significant reduction in systemic antibiotic exposure, with no treatment-related serious adverse events.
• Additional investment in the SER-155 Phase 2 study in allo-HSCT has been paused due to funding requirements, though the company aims to efficiently restart it.
• Initial clinical results for SER-155 in immune checkpoint-related enterocolitis (irEC) are expected in Q2 2026.
• SER-603, targeting inflammatory bowel disease (IBD), is in preclinical development and supported by a $500,000 grant from the Crohn's and Colitis Foundation (CCF) received in October 2023.
• The company is also developing SER-147 for infections in chronic liver disease (CLD) patients (preclinical) and an oral liquid formulation of SER-155 (LBP-LF) for ICU patients, supported by a CARB-X grant of up to $3.6 million awarded in July 2025.
• For the year ended December 31, 2025, the company reported a net income from continuing operations of $5.7 million, a significant improvement from a net loss of $125.8 million in 2024.
• Operating loss from continuing operations decreased to $94.0 million in 2025 from $121.3 million in 2024.
• Cash and cash equivalents stood at $45.8 million as of December 31, 2025, with an accumulated deficit of $972.4 million.
• Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern beyond Q3 2026.
• Cost reduction actions included a 25% workforce reduction in September 2025 and an additional 30% in February 2026, resulting in 45 employees as of March 1, 2026.
• A 1-for-20 reverse stock split was effected on April 21, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• Richard N. Kender was appointed Executive Chair and Interim Chief Executive Officer, Matthew Henn, Ph.D., as President and Chief Scientific Officer, and Kelly Brady, M.S., as Executive Vice President, Chief Operating Officer, effective March 2, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report. While clinical data for SER-155 is promising and the company has a strategic pivot, the 'going concern' warning and the pause in a key Phase 2 study due to funding issues overshadow the positive clinical developments and cost-cutting efforts.

Positives

• Successfully developed and obtained FDA approval for VOWST, the first orally administered microbiome biotherapeutic, demonstrating platform capability.
• SER-155 received Fast Track Designation in December 2023 and Breakthrough Therapy designation in December 2024, indicating regulatory recognition of its potential.
• Phase 1b study of SER-155 in allo-HSCT showed strong efficacy signals with a 77% relative risk reduction in bacterial BSIs and a significant reduction in systemic antibiotic exposure.
• SER-155 was generally well tolerated in Phase 1b, with no observed treatment-related serious adverse events.
• Exploratory biomarker data for SER-155 supported its intended therapeutic mechanisms, including improved epithelial integrity and immune homeostasis.
• Received a $500,000 grant from the Crohn's and Colitis Foundation (CCF) in October 2023 to support SER-603 research in IBD.
• Awarded a CARB-X grant of up to $3.6 million in July 2025 to develop an oral liquid formulation of SER-155 (LBP-LF) for medically vulnerable ICU patients.
• Reported a net income from continuing operations of $5.7 million for the year ended December 31, 2025, a significant improvement from prior year losses.
• Operating loss from continuing operations decreased to $94.0 million in 2025 from $121.3 million in 2024, reflecting cost containment efforts.
• Successfully completed a 1-for-20 reverse stock split in April 2025, regaining compliance with Nasdaq listing requirements.
• Maintains a valuable intellectual property estate with 22 active patent families and 33 issued U.S. patents.

Negatives

• Identified conditions and events that raise substantial doubt regarding the ability to continue as a going concern after Q3 2026.
• Additional investment in the SER-155 Phase 2 study in allo-HSCT has been paused due to funding needs, delaying its advancement.
• Incurred significant operating losses since inception, with an accumulated deficit of $972.4 million as of December 31, 2025.
• Requires substantial additional funding to advance product candidates and commercialize them, if approved, with no guarantee of availability on acceptable terms.
• Implemented significant cost reduction actions, including a 25% workforce reduction in September 2025 and an additional 30% in February 2026, which could impact productivity and morale.
• Has significant excess leased space under existing obligations, which may adversely affect financial condition and results of operations.
• Subject to a patent infringement lawsuit filed by Vedanta Biosciences, Inc. and The University of Tokyo regarding VOWST, seeking unspecified damages and injunctive relief.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company will need additional funding to advance product candidates and commercialize them; inability to raise capital or secure partnerships could lead to further cost-reduction measures, delays, or winding down operations.
• Expects to incur losses for the foreseeable future and may never achieve or maintain profitability.
• The total amount of Milestone Payments from the VOWST Transaction is subject to various risks and uncertainties.
• May not realize the anticipated benefits of the VOWST Transaction and faces new challenges as a smaller, less diversified company.
• Limited operating history may make it difficult to evaluate the success of the business and assess future viability.
• The company is early in its development efforts of product candidates, and its reverse translational platform may not lead to approvable or marketable drugs.
• Product candidates are based on live biotherapeutics, a novel approach that may face longer than expected regulatory review due to lack of experience by authorities.
• Clinical drug development is a risky, lengthy, and expensive process with an uncertain outcome, potentially leading to additional costs or delays.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent necessary regulatory approvals.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, shutdowns) could hinder timely product development, approval, or commercialization.
• Current and future legislation or regulation may increase the difficulty and cost for obtaining marketing approval and commercializing product candidates, and may adversely affect prices.
• Reliance on third parties to conduct clinical trials, who may not perform satisfactorily.
• Even if approved, product candidates may fail to achieve the degree of market acceptance necessary for commercial success.
• Faces substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• Inability to adequately protect proprietary technology or obtain and maintain issued patents could lead to direct competition.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel, which is challenging given recent management changes and workforce reductions.
• Risk of receiving future Nasdaq non-compliance notices or delisting.
• Executive officers, directors, and principal stockholders have the ability to significantly influence matters, potentially delaying or preventing a change in control.
• Sales of a substantial number of outstanding shares could cause the market price of common stock to drop significantly.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Provisions in the restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition more difficult.
• Designated forum provisions could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• No anticipated cash dividends, making capital appreciation the sole source of gain for stockholders.
• The price of common stock may be volatile and fluctuate substantially.
• Adverse or misleading opinions from securities analysts could cause the common stock price and trading volume to decline.
• Continued costs and management time devoted to public company compliance initiatives and corporate governance practices.
• Risk of information technology system failures, cyberattacks, or deficiencies in cybersecurity.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws could adversely affect the business.
• The evolving regulatory framework for AI Technologies may affect the business.
• Acquisitions, dispositions, joint ventures, or other strategic alternatives could disrupt the business, cause dilution, and otherwise harm the business.
• Past and potential future securities class action litigation may harm the business.
• Subject to complex and changing laws and regulations, exposing the company to potential liabilities, increased costs, and other adverse effects.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Ability to use net operating loss carryforwards and research and development credits to offset future taxable income or liabilities may be subject to certain limitations.

Future Outlook

The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. It anticipates requiring additional funding following the third quarter of 2026 and is actively seeking business development transactions and collaborations to support its pipeline, particularly for SER-155 and I&I programs. The company has paused further investment in the SER-155 Phase 2 study in allo-HSCT while seeking funding. Initial clinical results for SER-155 in irEC are expected in Q2 2026, and IND-readiness for LBP-LF is targeted by the end of 2026. Overall research and development and general and administrative expenses are projected to decrease in 2026 due to the conclusion of the TSA and cost reduction measures. The impact of recent and proposed U.S. healthcare legislation (IRA, OBBA, Trump administration policies) is expected to be significant and potentially negative for the pharmaceutical industry and the company's revenues. Compliance costs related to evolving ESG laws and regulations are also expected to increase.

Management Comments

• "Our current strategy prioritizes advancing our programs that target I&I indications."
• "We continue to seek funding for the Phase 2 study [of SER-155 in allo-HSCT]."
• "We are currently exploring potential collaborations related to those I&I disease programs."
• "We believe that our LBPs could represent a non-immunosuppressive treatment option for I&I diseases that are linked to colitis and could broadly address immune therapy toxicities, both of which represent significant unmet medical needs and potential commercial opportunities."
• "We believe that the data generated suggest that live biotherapeutics could provide a novel treatment modality that could benefit patients living with gut-related inflammatory and immune diseases that are not effectively addressed today."
• "We continue our efforts to obtain capital and other resources to support further development of SER-155 and our broader portfolio of live biotherapeutic product candidates with applications for inflammatory diseases."
• "We are evaluating a range of potential deal structures that we believe could leverage our live biotherapeutics expertise and success, as demonstrated by bringing VOWST from early development through FDA approval."
• "Management has concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these consolidated financial statements are issued."

Industry Context

StockSavvy.ai notes that Seres Therapeutics operates in the rapidly evolving live biotherapeutics space, a novel drug modality with significant potential but also regulatory uncertainties. The strategic shift towards inflammatory and immune diseases aligns with a broader industry trend of exploring microbiome-based therapies beyond infectious diseases, targeting large unmet medical needs in conditions like IBD and irEC. The company's success with VOWST, the first FDA-approved oral microbiome therapeutic, positions it as a leader in this niche, but it faces intense competition from both established pharmaceutical giants and other early-stage biotech firms. The pause in SER-155's Phase 2 infectious disease study due to funding highlights the capital-intensive nature of clinical development, a common challenge for clinical-stage biopharmaceutical companies. The increasing focus on antimicrobial resistance (AMR) by global health organizations, as mentioned in the filing, underscores the importance of therapies like SER-155 and LBP-LF, potentially offering a significant market opportunity if funding can be secured.

Comparison to Industry Standards

• VOWST, the company's previously developed product, was the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, setting a high benchmark for the company's platform in the novel live biotherapeutics field.
• The SER-155 Phase 1b study results, showing a 77% relative risk reduction in bacterial BSIs and significant reduction in systemic antibiotic exposure in allo-HSCT patients, represent a strong efficacy signal, especially considering that infections cause 19-28% of deaths in this patient population within 100 days post-transplant.
• SER-155 in irEC is positioned as a potential first-in-class therapy, aiming to offer a non-immunosuppressive treatment option, which contrasts with current reactive immunosuppressive approaches that can negatively impact cancer treatment.
• SER-603 for IBD aims to address microbiome functional disruptions and epithelial barrier compromise, offering a novel, non-immunosuppressive mechanism compared to many existing IBD therapies (biologics and small molecules) that primarily suppress immune responses and often face efficacy ceilings or durability issues.
• The development of LBP-LF to prevent bloodstream infections in ICU patients addresses a critical unmet need, as E. coli and other gut-derived bacteria cause up to 9 deaths per 100 ICU patients, and antimicrobial resistance is a top global public health threat with projected yearly deaths reaching 10 million by 2050.
• The accumulated deficit of $972.4 million and the 'going concern' warning are common for clinical-stage biotechnology companies but indicate significant financial challenges compared to more mature, revenue-generating pharmaceutical companies like Pfizer Inc. or Novartis Pharmaceuticals Corporation, where Dr. Ausiello and Mr. Graves, respectively, have served.

Management Changes

Corporate Governance

Legal Proceedings

• On August 20, 2024, Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint against the company and Nestlé S.A., Nestlé Health Science S.A., Nestlé Health Science US Holdings, Inc. and SPN in the United States District Court for the District of Delaware alleging that the making, sale and use of VOWST infringes on U.S. Patent Nos. 9,433,652, 9,662,381, 9,808,519, 10,555,978, and 11,090,343. The complaint seeks unspecified damages, fees, expenses and injunctive relief. The company believes the complaint is without merit and intends to defend itself vigorously.
• On April 25, 2017, the company filed a notice of opposition in the European Patent Office challenging the validity of a patent issued to The University of Tokyo. On November 18, 2022, The University of Tokyo requested termination of the appeal proceeding and revocation of its patent. On December 19, 2022, the Opposition Division officially terminated the appeal proceeding, and European Patent No. 2 575 835 B1 has been revoked in its entirety.
• On September 28, 2016, a purported stockholder filed a putative class action lawsuit (Mariusz Mazurek v. Seres Therapeutics, Inc., et.al.) in the U.S. District Court for the District of Massachusetts alleging false and misleading statements and omissions about the company's clinical trials for its then product candidate SER-109. This lawsuit has been dismissed by the court.

Related Party Transactions

• Completed the sale of the VOWST Business to Société des Produits Nestlé S.A. (SPN) and its designated affiliates (Nestlé Health Science) in September 2024.
• Received cash installment payments from Nestlé of $50 million on January 15, 2025, and $25 million on July 1, 2025 (offset by $1.4 million paid to Nestlé for employment obligations).
• Received a prepayment of a $60 million milestone (Prepaid Milestone) from SPN at closing, tied to $150 million worldwide annual net sales of VOWST, accruing interest at 10% per annum until achieved, then 5%.
• Future Milestone Payments from SPN include $125 million for $400 million net sales and $150 million for $750 million net sales, which will first offset accrued interest and the outstanding Prepaid Milestone balance.
• SPN purchased 714,285 shares of common stock for $15.0 million at $21.00 per share under a Securities Purchase Agreement, and has the right to designate one director to the company's board as long as it beneficially owns at least 10% of outstanding common stock.
• Entered into a Transition Services Agreement (TSA) with NESA (an affiliate of SPN) to provide manufacturing and administrative services until December 31, 2025, generating $13.3 million in reimbursement income in 2025.
• Accrued liabilities due to SPN related party were $3.3 million as of December 31, 2025, primarily related to Profit Sharing Payments, royalties under the MSK Agreement, VOWST post-marketing safety surveillance study costs, and a portion of the Waltham facility lease cost.
• Entered into a Cross-License Agreement with SPN, granting SPN licenses for VOWST-related intellectual property and receiving licenses for non-CDI field applications.
• Certain prior license agreements with Nestec, Ltd. and NHSc Pharma Partners were terminated upon mutual agreement.
• Nestlé purchased certain manufacturing and laboratory equipment from the company for $169,000 in 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and stock price volatility due to the 'going concern' warning and the pause in a key clinical trial. The influence of executive officers, directors, and principal stockholders remains significant.
• Employees have been significantly impacted by workforce reductions (25% in September 2025 and an additional 30% in February 2026), which could affect morale and retention. Management changes have also occurred.
• Patients may benefit from the potential development of new non-immunosuppressive treatment options for inflammatory and immune diseases and prevention of antimicrobial-resistant infections, but delays in the SER-155 Phase 2 study could impact future access.
• Creditors may view the 'going concern' warning as a heightened risk, potentially making it more difficult for the company to obtain future financing on favorable terms.
• Suppliers and partners may be hesitant to engage in new business or may impose less favorable terms due to concerns about the company's financial stability and ability to meet contractual obligations.

Next Steps

• Seek funding for the SER-155 Phase 2 study in allo-HSCT to enable its restart.
• Report initial clinical results for SER-155 in immune checkpoint-related enterocolitis (irEC) in Q2 2026.
• Advance preclinical development of SER-603 for inflammatory bowel disease (IBD), with IND-enabling activities ongoing.
• Continue research and development activities for SER-603, supported by the Crohn's and Colitis Foundation (CCF) grant.
• Advance preclinical development of SER-147 for chronic liver disease (CLD), with IND-enabling activities ready to progress.
• Continue development of the oral liquid formulation of SER-155 (LBP-LF) with CARB-X grant support, targeting IND-readiness by the end of 2026.
• Explore potential collaborations related to inflammatory and immune disease programs.
• Continue efforts to obtain capital and other resources to support further development of SER-155 and the broader portfolio of live biotherapeutic product candidates.
• Evaluate a range of potential deal structures to leverage live biotherapeutics expertise.
• Management team will continue to devote substantial time to compliance initiatives and corporate governance practices.
• The Audit Committee will continue to receive quarterly reports on cybersecurity risks and updates regarding significant incidents from the VP of IT.

Key Dates

Recommendation

The 'going concern' warning, indicating substantial doubt about the company's ability to continue operations beyond Q3 2026 without additional funding, is a critical red flag for investors. The pause in the Phase 2 study for SER-155, despite promising Phase 1b results, underscores severe financial constraints. While the company has promising early-stage pipeline candidates and a strategic pivot, the immediate financial instability and the need for significant capital raises in a challenging market environment present substantial risks that outweigh the potential long-term upside. The recent workforce reductions and excess leased space further highlight operational difficulties.

Keywords

Live Biotherapeutics, Microbiome, SER-155, SER-603, SER-147, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Immune Checkpoint-Related Enterocolitis, Allogeneic Hematopoietic Stem Cell Transplantation, Bloodstream Infections, Antimicrobial Resistance, Chronic Liver Disease, FDA Breakthrough Therapy, Fast Track Designation, Biopharmaceutical, Clinical-stage, Oncology, Immunology, Infectious Disease, Financial Health, Going Concern, Capital Raise, Workforce Reduction, Nasdaq Compliance